Clinical importance of the CYP2C1917 variant allele for voriconazole

British Journal of Clinical Pharmacology

Volumn 71, Issue 1, 2011, Pages 137-138

  Dolton, Michael J ^a   McLachlan, Andrew J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; TAMOXIFEN; VORICONAZOLE; ANTIFUNGAL AGENT; CYP2C19 PROTEIN, HUMAN; DRUG; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ALLELE; AREA UNDER THE CURVE; CONFIDENCE INTERVAL; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; GENOTYPE; HETEROZYGOSITY; HUMAN; LETTER; LUNG ASPERGILLOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; GENETICS; METABOLISM; NOTE;

ALLELES; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; HUMANS; PHARMACEUTICAL PREPARATIONS; PYRIMIDINES; TRIAZOLES;

EID: 78650070154     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03801.x     Document Type: Letter

References (11)

1. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010; 69: 222-30.
2. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, Van Burik J-A, Wingard JR, Patterson TF, America IDSo. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
3. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649-63.
4. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34.
5. Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009; 49: 196-204.
6. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
7. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
8. Miyakis S, Van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010; 16: 927-33.
9. Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf 2010; 9: 125-37.
10. Brüggemann RJM, Donnelly JP, Aarnoutse RE, Warris A, Blijlevens NMA, Mouton JW, Verweij PE, Burger DM. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008; 30: 403-11.
11. Wang G, Lei H-P, Li Z, Tan Z-R, Guo D, Fan L, Chen Y, Hu D-L, Wang D, Zhou H-H. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009; 65: 281-5.